Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CX-188 in Advanced Solid Tumors
NCT03706274Phase 1Withdrawn
- Sponsor
- CytomX
- Start
- Jan 2020
- Primary completion
- Dec 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CX-188 in solid tumor (2 arms), sponsored by CytomX. Primary endpoint: Dose-Limiting Toxicity at 21 days. Planned start Jan 2020; status: withdrawn.
02
Drugs
CX-188
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03706274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03706274.